← Leaderboards
Douglas G. Widman
Karyopharm Therapeutics, Inc.
$491,206
Attributed
$982,411
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
NIH$982,411 · 1
By mechanism
R44$982,411 · 1
Top collaborators
- Yosef Landesman1 shared
Most similar at Karyopharm Therapeutics, Inc.
Same institution · by research overlap
- Sharon Tamir$608,756
- Yosef Landesman$987,461
- Margaret S Lee$112,500
Others in their field
Other Emerging Leaders on “Adverse Event”
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Jean Macdonald · Dana-Farber Cancer Inst$26,990,229
- Michelle Lynn Sever · Rho Federal Systems Division, Inc.$26,732,375
- Barbara Halina Braffett · George Washington University$18,816,779
- Ionut Bebu · George Washington University$18,816,779
- Stacey Lynn Clardy · Utah State Higher Education System--University Of Utah$15,093,619
Research focus
Adverse EventAffectAfrican AmericanAntibodiesAnti-InflammatoryAttentionAutoantibodiesAutoimmune DiseasesAutoimmunityAutoreactive B CellAutoreactivityB Cell DifferentiationB-LymphocytesBone MarrowCancer CellCell SurvivalCellular BiologyClinical TrialsCollaborationsCombined Modality TherapyCommercializationComplexCritical PathwaysAchievement